NCT06779721

Brief Summary

The aim of this study is to evaluate sestrin-2 levels in children with obesity

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
89

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jun 2021

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 20, 2021

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 20, 2022

Completed
26 days until next milestone

Study Completion

Last participant's last visit for all outcomes

February 15, 2022

Completed
2.9 years until next milestone

First Submitted

Initial submission to the registry

January 13, 2025

Completed
3 days until next milestone

First Posted

Study publicly available on registry

January 16, 2025

Completed
Last Updated

January 17, 2025

Status Verified

January 1, 2025

Enrollment Period

7 months

First QC Date

January 13, 2025

Last Update Submit

January 16, 2025

Conditions

Obese Adolescents

Keywords

Antioxidantchildhood obesityinsulin resistancesestrin-2oxidative stress

Outcome Measures

Primary Outcomes (1)

  • Evaluation of sestrin-2 levels in obese and healthy participants

    From enrollment to the end of 6 months

Interventions

Sestrin-2OTHER

Sestrin-2 levels were studied in three different groups

Eligibility Criteria

Age10 Years - 18 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodProbability Sample
Study Population

Obese and healthy adolescents who admitted to Kayseri City Hospital

You may qualify if:

  • Obese adolescents Body mass index above the 95th percentile BMI Z-score above 2

You may not qualify if:

  • Primary hyperlipidemia Primary liver disease Hypothyroidism Diabetes

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Kayseri City Hospital

Kayseri, 38125, Turkey (Türkiye)

Location

Related Publications (1)

  • Soylu Ustkoyuncu P, Kocer D. Sestrin-2 levels and insulin resistance in childhood obesity. J Investig Med. 2025 Jul 7:10815589251359311. doi: 10.1177/10815589251359311. Online ahead of print.

    PMID: 40621934DERIVED

MeSH Terms

Conditions

Pediatric ObesityInsulin Resistance

Interventions

Sesn2 protein, rat

Condition Hierarchy (Ancestors)

ObesityOverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and SymptomsHyperinsulinismGlucose Metabolism DisordersMetabolic Diseases

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

January 13, 2025

First Posted

January 16, 2025

Study Start

June 20, 2021

Primary Completion

January 20, 2022

Study Completion

February 15, 2022

Last Updated

January 17, 2025

Record last verified: 2025-01

Locations

TU(1)